Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2018009622) LACTAM, CYCLIC UREA AND CARBAMATE, AND TRIAZOLONE DERIVATIVES AS POTENT AND SELECTIVE ROCK INHIBITORS
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

WHAT IS CLAIMED IS:

1. A compound of Formula (I):


or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof, wherein:

Ring A is independently selected from
and

Rin B is independently selected from


G is independently selected from N and CRJ;

M is independently selected from N and CR9;

X is independently selected from CRi, NR2, and O;

Y is independently selected from CR3 and N;

L is absent or independently selected from -NR4-, -C(0)NR4(CR4R4)n-, and -0-;

Ri is L-R5;


R3 is independently selected from H, Ci-4alkyl substituted with 0-4 Re, -(CH2)rORb,

(CH2)rS(0)pRc, -(CH2)rC(=0)Rb, -(CH2)rNRaRa, -(CH2)rCN, -(CH2)rC(=0)NRaRa, -(CH2)rNRaC(=0)Rb, -(CH2)rNRaC(=0)NRaRa, -(CH2)rNRaC(=0)ORb,

-(CH2)rOC(=0)NRaRa, -(CH2)rC(=0)ORb, -(CH2)rS(0)pNRaRa,

-(CH2)rNRaS(0)pNRaRa, -(CH2)rNRaS(0)pRc, (CH2)i-C3-6 carbocyclyl substituted with 0-3 Re, and -(CH2)r-heterocyclyl substituted with 0-3 Re;

R4 is independently selected from H and Ci-4alkyl substituted with 0-4 Re;

R5 is independently selected from C3-6 cycloalkyl, heterocyclyl, aryl and heteroaryl, each substituted with 1-5 R6;

alternatively, when L is -NR4-, -C(0)NR4-, R4 and R5 together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 1-5 R6;

R6 is independently selected from H, =0, F, CI, Br, Ci-4alkyl, C2-4alkenyl, C2-4alkynyl, nitro, -(CRdRd)rS(<%Rc,
-(CRdRd)rNRaS(0)i.Rc,

-(CRdRd)rORb, -(CRdRd)rCN, -(CRdRd)rNRaRa, -(CRdRd)rNRaC(=0)Rb,

-(CRdRd)rNRaC(=0)NRaRa, -(CRdRd)rNRaC(=0)ORb, -(CRdRd)rC(=0)ORb, -(CRdRd)rC(=0)NRaRa, -(CRdRd)rC(=0)Rb, -(CRdRd)rOC(=0)Rb,

-(CRdRd)rOC(=0)NRaRa, -(CRdRd)r-cycloalkyl, -(CRdRd)r-heterocyclyl, -(CRdRd)r-aryl, and -(CRdRd)r-heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is substituted with 0-4 Re;

R7 is independently selected from H, F, CI, Br, CN, Ci-4 alkyl substituted with 0-3 Re,

-(CH2)rORb, (CH2)rS(0)pRc, -(CH2)rC(=0)Rb, -(CH2)rNRaRa,

-(CH2)rC(=0)NRaRa, -(CH2)rC(=0)(CH2)rNRaRa, -(CH2)rCN,

-(CH2)rNRaC(=0)Rb, -(CH2)rNRaC(=0)ORb, -(CH2)rOC(=0)NRaRa,

-(CH2)rNRaC(=0)NRaRa, -(CH2)rC(=0)ORb, -(CH2)rS(0)pNRaRa,

-(CH2)rNRaS (O)pNRaRa, -(CH2)rNRaS(0)pRc, (CH2)i-C3-6 carbocyclyl substituted with 0-3 Re, and -(CH2)r-heterocyclyl substituted with 0-3 Re;

R8 is independently selected from H, F, CI, Br, -(CH2 ORb, (CH2)rS(0)PRc,

-(CH2)rC(=0)Rb, -(CH2)rNRaRa, -(CH2)rCN, -(CH2)rC(=0)NRaRa,

-(CH2)rNRaC(=0)Rb, -(CH2)rNRaC(=0)NRaRa, -(CH2)rNRaC(=0)ORb, -(CH2)rOC(=0)NRaRa, -(CH2)rC(=0)ORb, -(CH2)rS(0)pNRaRa,

-(CH2)rNRaS (O)pNRaRa, -(CH2)rNRaS(0)pRc, (CH2)i-C3-6 carbocyclyl substituted with 0-3 Re, and -(CH2)r-heterocyclyl substituted with 0-3 Re;

R9 is independently selected from H and Ci-4alkyl substituted with 0-4 Re;

Ra is independently selected from H, Ci-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re,

-(CH2)r-C3 iocarbocyclyl substituted with 0-5 Re, and -(CH2)r-heterocyclyl substituted with 0-5 Re; or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 Re;

Rb is independently selected from H, Ci-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re,

-(CH2)r-C3 iocarbocyclyl substituted with 0-5 Re, and -(CH2)r-heterocyclyl substituted with 0-5 Re;

Rc is independently selected from Ci-6 alkyl substituted with 0-5 Re, C2-6alkenyl

substituted with 0-5 Re, C2-6alkynyl substituted with 0-5 Re, C3-6carbocyclyl, and heterocyclyl;

Rd is independently selected from H and Ci-4alkyl substituted with 0-5 Re;

Re is independently selected from Ci-6 alkyl substituted with 0-5 Rf, C2-6 alkenyl, C2-6 alkynyl, -(CH2)r-C3-6 cycloalkyl, -(CH2)r-C4-6 heterocyclyl, -(CH2)r-aryl,

-(CH2)f heteroaiyl, F, CI, Br, CN, N02, =0, CO2H, -(CH2)rORf, S(0)PRf, C(=0)NRfRf, NRfC(=0)Rd, S(0)PNRfRf, NRfS(0)PRd, NRfC(=0)ORd, OC(=0)NRfRf and -(CH2)rNRfRf;

Rf is independently selected from H, F, CI, Br, CN, OH, Ci-salkyl, C3-6 cycloalkyl, and phenyl; or Rf and Rf together with the nitrogen atom to which they are both attached form a heterocyclic ring optionally substituted with Ci-4alkyl;

n, at each occurrence, is independently selected from 0, 1, 2, and 3;

p, at each occurrence, is independently selected from 0, 1, and 2; and

r is independently selected from 0, 1 , 2, 3, and 4.

2. The compound of claim 1 , having Formula (II):


or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein: Ring B is selected from


G is selected from N and CR7;

M is independently selected from N and CR9;

X is independently selected from CRi, NR2, and O;

L is absent or independently selected from -NR4-, -C(0)NR4(CR4R4)n-, and -0-; Ri is L-Rs;


R.3 is independently selected from H, Ci-4alkyl substituted with 0-4 Re, (CH2)r-C3-6 carbocyclyl substituted with 0-3 Re, and -(CH2)r-heterocyclyl substituted with 0-3 Re;

R4 is independently selected from H and Ci-4alkyl substituted with 0-4 Re;

R5 is independently selected from C3-6 cycloalkyl, heterocyclyl, aryl and heteroaryl, each substituted with 1-5 R6;

alternatively, when L is -NR4-, -C(0)NR4-, R4 and R5 together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 1-5 R6; R6 is independently selected from H, =0, F, CI, Br, Ci-4alkyl, C2-4alkenyl, C2-4alkynyl, nitro, -(CRdRd)rS(0)/JRc, -(CRdRd)rS(0)/JNRaRa, -(CRdRd)rNRaS(0)/JRc,

-(CRdRd)rORb, -(CRdRd)rCN, -(CRdRd)rNRaRa, -(CRdRd)rNRaC(=0)Rb,

-(CRdRd)rNRaC(=0)NRaRa, -(CRdRd)rNRaC(=0)ORb, -(CRdRd)rC(=0)ORb,

-(CRdRd)rC(=0)NRaRa, -(CRdRd)rC(=0)Rb, -(CRdRd)rOC(=0)Rb,

-(CRdRd)rOC(=0)NRaRa, -(CRdRd)r-cycloalkyl, -(CRdRd)r-heterocyclyl, -(CRdRd)r-aryl, and -(CRdRd)r-heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is substituted with 0-4 Re;

R7 is independently selected from H, F, CI, Br, CN, Ci-4 alkyl substituted with 0-3 Re,

R8 is independently selected from H, F, CI, Br, and -(CH2)rORb;

R9 is independently selected from H and Ci-4alkyl substituted with 0-4 Re;

Ra is independently selected from H, Ci-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re,

-(CH2)r-C3 iocarbocyclyl substituted with 0-5 Re, and -(CH2)r-heterocyclyl substituted with 0-5 Re; or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 Re;

Rb is independently selected from H, Ci-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re,

-(CH2)r-C3 iocarbocyclyl substituted with 0-5 Re, and -(CH2)r-heterocyclyl substituted with 0-5 Re;

Rc is independently selected from Ci-6 alkyl substituted with 0-5 Re, C2-6alkenyl

substituted with 0-5 Re, C2-6alkynyl substituted with 0-5 Re, C3-6carbocyclyl, and heterocyclyl;

Rd, at each occurrence, is independently selected from H and Ci-4alkyl substituted with 0-5 Re;

Re is independently selected from Ci-6 alkyl substituted with 0-5 Rf, C2-6 alkenyl, C2-6 alkynyl, -(CH2)r-C3-6 cycloalkyl, -(CH2)r-C4-6 heterocyclyl, -(CH2)r-aryl, -(CH2)i ieteroaryl, F, CI, Br, CN, NO2, =0, CO2H, -(CH2)rORf, S(0)PRf, C(=0)NRfRf, NRfC(=0)Rd, S(0)PNRfRf, NRfS(0)PRd, NRfC(=0)ORd,

OC(=0)NRfRf and -(CH2)rNRfRf;

Rf is independently selected from H, F, CI, Br, CN, OH, Ci-salkyl, C3-6 cycloalkyl, and phenyl; or Rf and Rf together with the nitrogen atom to which they are both attached form a heterocyclic ring optionally substituted with Ci-4alkyl;

n, at each occurrence, is independently selected from 0, 1 , and 2;

p, at each occurrence, is independently selected from 0, 1, and 2; and

r is independently selected from 0, 1 , 2, 3, and 4.

The compound of claim 1 , having Formula (III):


or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein: L is absent or independently from -NR4-, -C(0)NR4(CR4R4)n-, and -0-;

M is independently selected from N and CH;

R4 is independently selected from H and Ci-4alkyl substituted with 0-4 Re;

R5 is independently selected from C3-6 cycloalkyl, heterocyclyl, aryl and heteroaryl, each substituted with 1-5 R6;

alternatively, when L is -NR -, -C(0)NR.4-, R4 and R5 together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 1-5 R6;

R6 is independently selected from H, =0, F, CI, Br, Ci-4alkyl, C2-4alkenyl, C2-4alkynyl, nitro, -(CRdRd)rS(<%Rc,
-(CRdRd)rNRaS(0)i.Rc,

-(CRdRd)rORb, -(CRdRd)rCN, -(CRdRd)rNRaRa, -(CRdRd)rNRaC(=0)Rb,

-(CRdRd)rNRaC(=0)NRaRa, -(CRdRd)rNRaC(=0)ORb, -(CRdRd)rC(=0)ORb,

-(CRdRd)rC(=0)NRaRa, -(CRdRd)rC(=0)Rb, -(CRdRd)rOC(=0)Rb,

-(CRdRd)rOC(=0)NRaRa, -(CRdRd)r-cycloalkyl, -(CRdRd)r-heterocyclyl, -(CRdRd)r-aryl, and -(CRdRd)r-heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is substituted with 0-4 Re;

Ra is independently selected from H, Ci-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re,

-(CH2)r-C3 iocarbocyclyl substituted with 0-5 Re, and -(CH2)r-heterocyclyl substituted with 0-5 Re; or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 Re;

Rb is independently selected from H, Ci-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re,

-(CH2)r-C3 iocarbocyclyl substituted with 0-5 Re, and -(CH2)r-heterocyclyl substituted with 0-5 Re;

Rc is independently selected from Ci-6 alkyl substituted with 0-5 Re, C2-6alkenyl

substituted with 0-5 Re, C2-6alkynyl substituted with 0-5 Re, C3-6carbocyclyl, and heterocyclyl;

Rd, at each occurrence, is independently selected from H and Ci-4alkyl substituted with 0-5 Re;

Re is independently selected from Ci-6 alkyl substituted with 0-5 Rf, C2-6 alkenyl, C2-6 alkynyl, -(CH2)r-C3-6 cycloalkyl, -(CH2)r-C4-6 heterocyclyl, -(CH2)r-aryl, -(CH2)i ieteroaryl, F, CI, Br, CN, NO2, =0, CO2H, -(CH2)rORf, S(0)PRf, C(=0)NRfRf, NRfC(=0)Rd, S(0)PNRfRf, NRfS(0)PRd, NRfC(=0)ORd,

OC(=0)NRfRf and -(CH2)rNRfRf;

Rf is independently selected from H, F, CI, Br, CN, OH, Ci-salkyl, C3-6 cycloalkyl, and phenyl; or Rf and Rf together with the nitrogen atom to which they are both attached form a heterocyclic ring optionally substituted with Ci-4alkyl;

p, at each occurrence, is independently selected from 0, 1, and 2; and r is independently selected from 0, 1, 2, 3, and 4.

4. The compound of claim 3 or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:

L is independently selected from -NR.4-, -C(0)NR.4(CH2)o-i-, and -0-;

R.4 is independently selected from H and Ci-4alkyl substituted with 0-4 Re; R5 is independently selected from



R6 is independently selected from H, =0, F, CI, Br, Ci-4alkyl, C2-4alkenyl, C2-4alkynyl, nitro, -(CHRd)rS(0)/JRc, -(CHRd)rS(0)/JNRaRa, -(CHRd)rNRaS(0)/JRc,

-(CHRd)rORb, -(CHRd)rCN, -(CHRd)rNRaRa, -(CHRd)rNRaC(=0)Rb,

-(CHRd)rNRaC(=0)NRaRa, -(CHRd)rNRaC(=0)ORb, -(CHRd)rC(=0)ORb, -(CHRd)rC(=0)NRaRa, -(CHRd)rOC(=0)NRaRa, -(CHRd)rC(=0)Rb, -(CHRd)r

OC(=0)Rb, -(CHRd)r-cycloalkyl, -(CHRd)i ieterocyclyl, -(CHRd)r-aryl, and -(CHRd)r-heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is substituted with 0-4 Re;

R6a is independently selected from H, CM alkyl,
-S(O vTRaRa, -C(=0)ORb, -(CH2)rC(=0)Rb, -(CH2)r-cycloalkyl, -(CH2)i ieterocyclyl, -(CH2)i-aryl, and -(CH2)r-heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is substituted with 0-4 Re;

Ra, at each occurrence, is independently selected from H, Ci-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re, -(CH2)r-C3 iocarbocyclyl substituted with 0-5 Re, and -(CH2)r-heterocyclyl substituted with 0-5 Re; or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 Re;

Rb, at each occurrence, is independently selected from H, Ci-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re, -(CH2)r-C3 iocarbocyclyl substituted with 0-5 Re, and -(CH2)r-heterocyclyl substituted with 0-5 Re;

Rc, at each occurrence, is independently selected from Ci-6 alkyl substituted with 0-5 Re, C2-6alkenyl substituted with 0-5 Re, C2-6alkynyl substituted with 0-5 Re,

C3-6carbocyclyl, and heterocyclyl;

Rd, at each occurrence, is independently selected from H and Ci-4alkyl substituted with 0-5 Re;

Re, at each occurrence, is independently selected from Ci-6 alkyl substituted with 0-5 Rf, C2-6 alkenyl, C2-6 alkynyl, -(CH2)r-C3-6 cycloalkyl, -(CH2)r-C4-6 heterocyclyl, F, CI, Br, CN, NO2, =0, CO2H, -(CH2)rORf, S(0)PRf, S(0)PNRfRf, and -(CH2)rNRfRf;

Rf, at each occurrence, is independently selected from H, F, CI, Br, CN, OH, C1-5 alkyl, C3-6 cycloalkyl, and phenyl; or Rf and Rf together with the nitrogen atom to which they are both attached form a heterocyclic ring optionally substituted with Ci-4alkyl;

p, at each occurrence, is independently selected from zero, 1 , and 2; and

r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.

5. The compound of claim 3, or a stereoisomer, a tautomer, or a

pharmaceutically acceptable salt thereof, wherein:

L is independently selected from -NR4- and -C(0)NR4-;

R4 and R5 are taken together with the nitrogen atom to which they are attached to form a heterocycle selected from


R6 is independently selected from H, =0, F, CI, Br, Ci-4alkyl, C2-4alkenyl, C2-4alky

nitro, -(CHRd)rS(0)/JRc, -(CHRd)rS(0)/JNRaRa, -(CHRd)rNRaS(0)/JRc,

-(CHRd)rORb, -(CHRd)rCN, -(CHRd)rNRaRa, -(CHRd)rNRaC(=0)Rb,

-(CHRd)rNRaC(=0)NRaRa, -(CHRd)rNRaC(=0)ORb, -(CHRd)rC(=0)ORb,

-(CHRd)rC(=0)NRaRa, -(CHRd)rOC(=0)NRaRa, -(CHRd)rC(=0)Rb, -(CHRd)r

OC(=0)Rb, -(CHRd)r-cycloalkyl, -(CHRd)i ieterocyclyl, -(CHRd)r-aryl, and

-(CHRd)r-heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is substituted with 0-4 Re;

R6a is independently selected from H, CM alkyl,
-S(O vTRaRa, -C(=0)ORb, -(CH2)rC(=0)Rb, -(CH2)r-cycloalkyl, -(CH2)i-heterocyclyl, -(CH2)i-aryl, and

-(CH2)r-heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is substituted with 0-4 Re;

Ra, at each occurrence, is independently selected from H, Ci-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re, -(CH2)r-C3 iocarbocyclyl substituted with 0-5 Re, and -(CH2)r-heterocyclyl substituted with 0-5 Re; or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 Re;

Rb, at each occurrence, is independently selected from H, Ci-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re, -(CH2)r-C3 iocarbocyclyl substituted with 0-5 Re, and -(CH2)r-heterocyclyl substituted with 0-5 Re;

Rc, at each occurrence, is independently selected from Ci-6 alkyl substituted with 0-5 Re, C2-6alkenyl substituted with 0-5 Re, C2-6alkynyl substituted with 0-5 Re, C3-6carbocyclyl, and heterocyclyl;

Rd, at each occurrence, is independently selected from H and Ci-4alkyl substituted with 0-5 Re;

Re, at each occurrence, is independently selected from Ci-6 alkyl substituted with 0-5 Rf, C2-6 alkenyl, C2-6 alkynyl, -(CH2)r-C3-6 cycloalkyl, -(CH2)r-C4-6 heterocyclyl, F, CI, Br, CN, N02, =0, C02H, -(CH2)rORf, S(0)PRf, S(0)PNRfRf, and -(CH2)rNRfRf;

Rf, at each occurrence, is independently selected from H, F, CI, Br, CN, OH, C1-5 alkyl, C3-6 cycloalkyl, and phenyl; or Rf and Rf together with the nitrogen atom to which they are both attached form a heterocyclic ring optionally substituted with

Ci-4alkyl;

p, at each occurrence, is independently selected from zero, 1, and 2; and

r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.

6. The compound of claim 3 or a stereoisomer, a tautomer, or a

pharmaceutically acceptable salt thereof, wherein:

L is -0-;

R.5 is independently selected from


R6 is independently selected from H, =0, F, CI, Br, Ci-4alkyl, C2-4alkenyl, C2-4alkynyl, nitro,
-(CHRd)rNRaS((¾Rc,

-(CHRd)rORb, -(CHRd)rCN, -(CHRd)rNRaRa, -(CHRd)rNRaC(=0)Rb,

-(CHRd)rNRaC(=0)NRaRa, -(CHRd)rNRaC(=0)ORb, -(CHRd)rC(=0)ORb, -(CHRd)rC(=0)NRaRa, -(CHRd)rOC(=0)NRaRa, -(CHRd)rC(=0)Rb, -(CHRd)r

OC(=0)Rb, -(CHRd)r-cycloalkyl, -(CHRd)i ieterocyclyl, -(CHRd)r-aryl, and

-(CHRd)r-heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is substituted with 0-4 Re;

Ra, at each occurrence, is independently selected from H, Ci-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re,

-(CH2)r-C3 iocarbocyclyl substituted with 0-5 Re, and -(CH2)r-heterocyclyl substituted with 0-5 Re; or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 Re;

Rb, at each occurrence, is independently selected from H, Ci-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re,

-(CH2)r-C3 iocarbocyclyl substituted with 0-5 Re, and -(CH2)r-heterocyclyl substituted with 0-5 Re;

Rc, at each occurrence, is independently selected from Ci-6 alkyl substituted with 0-5 Re,

C2-6alkenyl substituted with 0-5 Re, C2-6alkynyl substituted with 0-5 Re,

C3-6carbocyclyl, and heterocyclyl;

Rd, at each occurrence, is independently selected from H and Ci-4alkyl substituted with

0-5 Re;

Re, at each occurrence, is independently selected from Ci-6 alkyl substituted with 0-5 Rf, C2-6 alkenyl, C2-6 alkynyl, -(CH2)r-C3-6 cycloalkyl, -(CH2)r-C4-6 heterocyclyl, F, CI, Br, CN, NO2, =0, CO2H, -(CH2)rORf, S(0)PRf, S(0)PNRfRf, and -(CH2)rNRfRf;

Rf, at each occurrence, is independently selected from H, F, CI, Br, CN, OH, C1-5 alkyl, C3-6 cycloalkyl, and phenyl; or Rf and Rf together with the nitrogen atom to which they are both attached form a heterocyclic ring optionally substituted with Ci-4alkyl;

p, at each occurrence, is independently selected from zero, 1 , and 2; and

r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.

7. The compound of claim 2 having Formula (IV):


or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:

R4 is independently selected from H and Ci-4alkyl substituted with 0-4 Re;

R5 is independently selected from C3-6 cycloalkyl, heterocyclyl, aryl and heteroaryl, each substituted with 1-5 R6;

R6 is independently selected from H, =0, F, CI, Br, Ci-4alkyl, C2-4alkenyl, C2-4alkynyl, nitro,
-(CRdRd)rNRaS(0)i.Rc,

-(CRdRd)rORb, -(CRdRd)rCN, -(CRdRd)rNRaRa, -(CRdRd)rNRaC(=0)Rb,

-(CRdRd)rNRaC(=0)NRaRa, -(CRdRd)rNRaC(=0)ORb, -(CRdRd)rC(=0)ORb,

-(CRdRd)rC(=0)NRaRa, -(CRdRd)rC(=0)Rb, -(CRdRd)rOC(=0)Rb,

-(CRdRd)rOC(=0)NRaRa, -(CRdRd)r-cycloalkyl, -(CRdRd)r-heterocyclyl,

-(CRdRd)r-aryl, and -(CRdRd)r-heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is substituted with 0-4 Re;

Ra is independently selected from H, Ci-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re,

-(CH2)r-C3 iocarbocyclyl substituted with 0-5 Re, and -(CH2)r-heterocyclyl substituted with 0-5 Re; or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 Re;

Rb is independently selected from H, Ci-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re,

-(CH2)r-C3 iocarbocyclyl substituted with 0-5 Re, and -(CH2)r-heterocyclyl substituted with 0-5 Re;

Rc is independently selected from Ci-6 alkyl substituted with 0-5 Re, C2-6alkenyl

substituted with 0-5 Re, C2-6alkynyl substituted with 0-5 Re, C3-6carbocyclyl, and heterocyclyl;

Re is independently selected from Ci-6 alkyl substituted with 0-5 Rf, C2-6 alkenyl, C2-6 alkynyl, -(CH2)r-C3-6 cycloalkyl, -(CH2)r-C4-6 heterocyclyl, -(CH2)r-aryl, -(CH2)i ieteroaryl, F, CI, Br, CN, NO2, =0, CO2H, -(CH2)rORf, S(0)PRf,

C(=0)NRfRf, NRfC(=0)Rd, S(0)PNRfRf, NRfS(0)PRd, NRfC(=0)ORd,

OC(=0)NRfRf and -(CH2)rNRfRf;

Rf is independently selected from H, F, CI, Br, CN, OH, Ci-salkyl, C3-6 cycloalkyl, and phenyl; or Rf and Rf together with the nitrogen atom to which they are both attached form a heterocyclic ring optionally substituted with Ci-4alkyl;

n, at each occurrence, is independently selected from 0 and 1 ;

p, at each occurrence, is independently selected from 0, 1, and 2; and

r is independently selected from 0, 1 , 2, 3, and 4.

8. The compound of claim 2, having Formula (V):

or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein: R.3 is independently selected from H, Ci-4alkyl substituted with 0-4 Re, -(CH2)rORb,

(CH2)rS(0)pRc, -(CH2)rC(=0)Rb, -(CH2)rNRaRa, -(CH2)rCN, -(CH2)rC(=0)NRaRa, -(CH2)rNRaC(=0)Rb, -(CH2)rNRaC(=0)NRaRa, -(CH2)rNRaC(=0)ORb,

-(CH2)rOC(=0)NRaRa, -(CH2)rC(=0)ORb, -(CH2)rS(0)pNRaRa,

-(CH2)rNRaS(0)pNRaRa, -(CH2)rNRaS(0)pRc, (CH2)i-C3-6 carbocyclyl substituted with 0-3 Re, and -(CH2)r-heterocyclyl substituted with 0-3 Re;

Ra is independently selected from H, Ci-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re,

-(CH2)r-C3 iocarbocyclyl substituted with 0-5 Re, and -(CH2)r-heterocyclyl substituted with 0-5 Re; or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 Re;

Rb is independently selected from H, Ci-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re,

-(CH2)r-C3 iocarbocyclyl substituted with 0-5 Re, and -(CH2)r-heterocyclyl substituted with 0-5 Re;

Rc is independently selected from Ci-6 alkyl substituted with 0-5 Re, C2-6alkenyl

substituted with 0-5 Re, C2-6alkynyl substituted with 0-5 Re, C3-6carbocyclyl, and heterocyclyl;

Re is independently selected from Ci-6 alkyl substituted with 0-5 Rf, C2-6 alkenyl, C2-6 alkynyl, -(CH2)r-C3-6 cycloalkyl, -(CH2)r-C4-6 heterocyclyl, -(CH2)i-aryl,

-(CH2)i ieteroaryl, F, CI, Br, CN, NO2, =0, CO2H, -(CH2)rORf, S(0)PRf,

C(=0)NRfRf, NRfC(=0)Rd, S(0)PNRfRf, NRfS(0)PRd, NRfC(=0)ORd,

OC(=0)NRfRf and -(CH2)rNRfRf;

Rf is independently selected from H, F, CI, Br, CN, OH, Ci-salkyl, C3-6 cycloalkyl, and phenyl; or Rf and Rf together with the nitrogen atom to which they are both attached form a heterocyclic ring optionally substituted with Ci-4alkyl;

p, at each occurrence, is independently selected from 0, 1, and 2; and

r is independently selected from 0, 1 , 2, 3, and 4.

The compound of claim 1 , having Formula (VI):


or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:

Ring B is selected from


G is selected from N and CR7;

M is independently selected from N and CR9;

R3 is independently selected from H, Ci-4alkyl substituted with 0-4 Re, -(CH2)rORb,

(CH2)rS(0)pRc, -(CH2)rC(=0)Rb, -(CH2)rNRaRa, -(CH2)rCN, -(CH2)rC(=0)NRaRa, -(CH2)rNRaC(=0)Rb, -(CH2)rNRaC(=0)NRaRa, -(CH2)rNRaC(=0)ORb,

-(CH2)rOC(=0)NRaRa, -(CH2)rC(=0)ORb, -(CH2)rS(0)pNRaRa,

-(CH2)rNRaS(0)PNRaRa,
(CH2)i-C3-6 carbocyclyl substituted with 0-3 Re, and -(CH2)r-heterocyclyl substituted with 0-3 Re;

R4 is independently selected from H and Ci-4alkyl substituted with 0-4 Re;

R5 is independently selected from C3-6 cycloalkyl, heterocyclyl, aryl and heteroaryl, each substituted with 1-5 R6;

R6 is independently selected from H, =0, F, CI, Br, Ci-4alkyl, C2-4alkenyl, C2-4alkynyl, nitro,
-(CRdRd)rS((¾NRaRa, -(CRdRd)rNRaS((¾Rc,

-(CRdRd)rORb, -(CRdRd)rCN, -(CRdRd)rNRaRa, -(CRdRd)rNRaC(=0)Rb,

-(CRdRd)rNRaC(=0)NRaRa, -(CRdRd)rNRaC(=0)ORb, -(CRdRd)rC(=0)ORb, -(CRdRd)rC(=0)NRaRa, -(CRdRd)rC(=0)Rb, -(CRdRd)rOC(=0)Rb,

-(CRdRd)rOC(=0)NRaRa, -(CRdRd)r-cycloalkyl, -(CRdRd)r-heterocyclyl, -(CRdRd)r-aryl, and -(CRdRd)r-heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is substituted with 0-4 Re;

R7 is independently selected from H, F, CI, Br, CN, C 1-4 alkyl substituted with 0-3 Re,

R8 is independently selected from H, F, CI, Br, and -(CH2)rORb;

R9 is independently selected from H and Ci-4alkyl substituted with 0-4 Re;

Ra is independently selected from H, Ci-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re,

-(CH2)r-C3-iocarbocyclyl substituted with 0-5 Re, and -(CH2)r-heterocyclyl substituted with 0-5 Re; or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 Re;

Rb is independently selected from H, Ci-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re,

-(CH2)r-C3-iocarbocyclyl substituted with 0-5 Re, and -(CH2)r-heterocyclyl substituted with 0-5 Re;

Rc is independently selected from Ci-6 alkyl substituted with 0-5 Re, C2-6alkenyl

substituted with 0-5 Re, C2-6alkynyl substituted with 0-5 Re, C3-6carbocyclyl, and heterocyclyl;

Re is independently selected from Ci-6 alkyl substituted with 0-5 Rf, C2-6 alkenyl, C2-6 alkynyl, -(CH2)r-C3-6 cycloalkyl, -(CH2)r-C4-6 heterocyclyl, -(CH2)r-aryl, -(CH2)i ieteroaryl, F, CI, Br, CN, NO2, =0, CO2H, -(CH2)rORf, S(0)PRf,

C(=0)NRfRf, NRfC(=0)Rd, S(0)PNRfRf, NRfS(0)PRd, NRfC(=0)ORd,

OC(=0)NRfRf and -(CH2)rNRfRf;

Rf is independently selected from H, F, CI, Br, CN, OH, Ci-salkyl, C3-6 cycloalkyl, and phenyl; or Rf and Rf together with the nitrogen atom to which they are both attached form a heterocyclic ring optionally substituted with Ci-4alkyl;

n, at each occurrence, is independently selected from 0 and 1 ;

p, at each occurrence, is independently selected from 0, 1, and 2; and

r is independently selected from 0, 1, 2, 3, and 4.

The compound of claim 1, having Formula (VII):


or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:

Ring B is selected from


G is selected from N and CR7;

M is independently selected from N and CR9;

R3 is independently selected from H, Ci-4alkyl substituted with 0-4 Re, -(CH2)rORb,

(CH2)rS(0)pRc, -(CH2)rC(=0)Rb, -(CH2)rNRaRa, -(CH2)rCN, -(CH2)rC(=0)NRaRa, -(CH2)rNRaC(=0)Rb, -(CH2)rNRaC(=0)NRaRa, -(CH2)rNRaC(=0)ORb,

-(CH2)rOC(=0)NRaRa, -(CH2)rC(=0)ORb, -(CH2)rS(0)pNRaRa,

-(CH2)rNRaS(0)PNRaRa,
(CH2)i-C3-6 carbocyclyl substituted with 0-3 Re, and -(CH2)r-heterocyclyl substituted with 0-3 Re;

R4 is independently selected from H and Ci-4alkyl substituted with 0-4 Re;

R5 is independently selected from C3-6 cycloalkyl, heterocyclyl, aryl and heteroaryl, each substituted with 1-5 R6;

R6 is independently selected from H, =0, F, CI, Br, Ci-4alkyl, C2-4alkenyl, C2-4alkynyl, nitro,
-(CRdRd)rS((¾NRaRa, -(CRdRd)rNRaS((¾Rc,

-(CRdRd)rORb, -(CRdRd)rCN, -(CRdRd)rNRaRa, -(CRdRd)rNRaC(=0)Rb,

-(CRdRd)rNRaC(=0)NRaRa, -(CRdRd)rNRaC(=0)ORb, -(CRdRd)rC(=0)ORb, -(CRdRd)rC(=0)NRaRa, -(CRdRd)rC(=0)Rb, -(CRdRd)rOC(=0)Rb,

-(CRdRd)rOC(=0)NRaRa, -(CRdRd)r-cycloalkyl, -(CRdRd)r-heterocyclyl, -(CRdRd)r-aryl, and -(CRdRd)r-heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is substituted with 0-4 Re;

R7 is independently selected from H, F, CI, Br, CN, C 1-4 alkyl substituted with 0-3 Re,

R8 is independently selected from H, F, CI, Br, and -(CH2)rORb;

R9 is independently selected from H and Ci-4alkyl substituted with 0-4 Re;

Ra is independently selected from H, Ci-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re,

-(CH2)r-C3-iocarbocyclyl substituted with 0-5 Re, and -(CH2)r-heterocyclyl substituted with 0-5 Re; or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 Re;

Rb is independently selected from H, Ci-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re,

-(CH2)r-C3-iocarbocyclyl substituted with 0-5 Re, and -(CH2)r-heterocyclyl substituted with 0-5 Re;

Rc is independently selected from Ci-6 alkyl substituted with 0-5 Re, C2-6alkenyl

substituted with 0-5 Re, C2-6alkynyl substituted with 0-5 Re, C3-6carbocyclyl, and heterocyclyl;

Re is independently selected from Ci-6 alkyl substituted with 0-5 Rf, C2-6 alkenyl, C2-6 alkynyl, -(CH2)r-C3-6 cycloalkyl, -(CH2)r-C4-6 heterocyclyl, -(CH2)r-aryl, -(CH2)i ieteroaryl, F, CI, Br, CN, NO2, =0, CO2H, -(CH2)rORf, S(0)PRf,

C(=0)NRfRf, NRfC(=0)Rd, S(0)PNRfRf, NRfS(0)PRd, NRfC(=0)ORd,

OC(=0)NRfRf and -(CH2)rNRfRf;

Rf is independently selected from H, F, CI, Br, CN, OH, Ci-salkyl, C3-6 cycloalkyl, and phenyl; or Rf and Rf together with the nitrogen atom to which they are both attached form a heterocyclic ring optionally substituted with Ci-4alkyl;

n, at each occurrence, is independently selected from 0 and 1 ;

p, at each occurrence, is independently selected from 0, 1, and 2; and

r is independently selected from 0, 1 , 2, 3, and 4.

11. A pharmaceutical composition comprising one or more compounds according to any one of claims 1-10 and a pharmaceutically acceptable carrier or diluent.

12. A compound according to any one of claims 1 -10 for use in therapy.

13. Use of a compound according to any one of claims 1 -10 for prophylaxis and/or treatment of disorders associated with aberrant Rho kinase activity.

14. The use of claim 13, wherein said disorder is selected from the group consisting of a cardiovascular disorder, a smooth muscle related disorder, a fibrotic disease, an inflammatory disease, neuropathic disorders, oncologic disorders, and an autoimmune disorder.

15. The use of claim 14, wherein said cardiovascular disorder is selected from the group consisting of angina, atherosclerosis, stroke, cerebrovascular disease, heart failure, coronary artery disease, myocardial infarction, peripheral vascular disease, stenosis, vasospasm, hypertension and pulmonary hypertension.